Drug Profile
Duvelisib - Secura Bio
Alternative Names: ABBV-954; COPIKTRA; INK-1197; IPI-145; VS-0145; YHI-1702Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Intellikine
- Developer AbbVie; CSPC Pharmaceutical Group; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Secura Bio; Verastem Oncology; Yakult Honsha
- Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Purines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia
- Registered Follicular lymphoma
- Phase III Non-Hodgkin's lymphoma
- Phase II COVID 2019 infections; Haematological malignancies; Peripheral T-cell lymphoma; Squamous cell cancer
- Phase I/II Malignant melanoma
- Phase I Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Lymphoma; Solid tumours; T-cell lymphoma
- Discontinued Allergic asthma; Rheumatoid arthritis
Most Recent Events
- 22 Dec 2023 Secura Bio completes a phase II PRIMO trial in Peripheral T-cell lymphoma (Second-line therapy or greater) in Germany, Italy, United Kingdom, Japan, USA (PO) (NCT03372057) (EudraCT2019-001123-13)
- 25 Jul 2023 Secura Bio completes phase II TEMPO trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA, Czech Republic, Germany, Italy, South Korea, Poland, Russia and United Kingdom (NCT04038359)
- 08 Jun 2023 Updated efficacy and adverse event data from the phase II PRIMO trial in Peripheral T-cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)